168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study

S.A Hurvitz,A Bardia,K Punie,K Kalinsky,J Cortés,J O'Shaughnessy,L.A Carey,H.S Rugo,O.K Yoon,Y Pan,R.J Delaney,S Hofsess,P Hodgkins,S-C Phan,V Dieras

doi:10.1016/j.annonc.2022.03.187

168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study

S.A Hurvitz, A Bardia + Show 13 more

Open Access

https://doi.org/10.1016/j.annonc.2022.03.187

Copy DOI

Journal: Annals of Oncology	Publication Date: May 1, 2022
Citations: 13

Affiliation: University of California, Los Angeles, Massachusetts General Hospital, KU Leuven, Emory University, GEICAM – Spanish Breast Cancer Group, Texas Oncology, University North, University of California, San Francisco, Gilead Sciences (United States)

#Sacituzumab Govitecan #Metastatic Triple-negative Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

HER2 IHC1+ or IHC2+ and in situ hybridization (ISH)-negative results are sometimes referred to as HER2-Low. SG is a novel antibody-drug conjugate composed of an anti–Trop-2 antibody coupled to SN-38 via a proprietary, hydrolyzable linker. SG is approved in mTNBC for the second line (2L) onwards. In the ASCENT study, SG had significant progression-free survival (PFS) and overall survival (OS) benefit vs chemotherapy of physician’s choice (TPC). This ASCENT post hoc subgroup analysis evaluates SG efficacy in HER2 IHC0 and HER2-Low mTNBC.

Full Text